User:Reph-415: Difference between revisions

HOW
Names
	Other names WHY
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Infobox references

Content deleted Content added

Inline

Revision as of 12:41, 7 August 2023

Hi
I have tons of sexual intercourse all the time.^{[citation needed]}

Iboga alkaloid - Probably should be renamed to either "iboga-type alkaloid" or "substituted ibogamines". I submitted an attempt at making the article more detailed, and more sourced. I also (kind of) removed a weird attempt at promoting synthetic abominations that have little to do with iboga itself (18-MC).

Iboluteine (ibogaine pseudoindoxyl) - An ibogaine oxydation product, analogous to the poorly studied opioid mitragynine pseudoindoxyl. Iboluteine and related metabolites possibly contribute to iboga's therapeutic effects. UPDATE : Unfortunately, research about iboga and its alkaloids has come to a crawling stop because of insane anti-drug propaganda from france and north america.

There are many similar and/or contradicting hypotheses about monoamine transporter binding sites, here are some of them.

SERT NAMs : paroxetine and escitalopram [1] (see allosteric serotonin reuptake inhibitor)
SERT NAM / "partial releaser" : 4-Trifluoromethyl-Methcathinone (4-TFMMC) [2] CID:71550921
SERT PAM / "reuptake enhancer" : tianeptine (putative)
SERT PAM / "reuptake enhancer" : compound 7a [3] CID:71462111

Difluoropine, "inward-facing" reuptake inhibitor
Vanoxerine, "inward-facing" reuptake inhibitor
Modafinil, "inward-facing" reuptake inhibitor
SoRI-20041, "antagonist-like" reuptake inhibitor that, counterintuitively, doesn't antagonize dextroamphetamine-mediated (transporter-mediated) dopamine release.

Selegiline, (-)-PPAP, and (-)-BPAP, "monoamine release enhancers"
PCP and RTI-4793-14 bind to an allosteric modulator site on monoamine transporters : PCP site 2

@@ Line 79: / Line 79: @@
 * [[Vanoxerine]], "inward-facing" reuptake inhibitor
 * [[Modafinil]], "inward-facing" reuptake inhibitor
-* [[SoRI-20041]], "antagonist-like" reuptake inhibitor that counterintuitively ''doesn't antagonize'' [[amphetamine]]-mediated (transporter-mediated) dopamine release.
+* [[SoRI-20041]], "antagonist-like" reuptake inhibitor that, counterintuitively, ''doesn't'' antagonize [[dextroamphetamine]]-mediated ([[Reverse transport|transporter-mediated]]) dopamine release.
 ===Others===